Academic Journal
Reversing uL3-mediated chemoresistance through synergistic combination of 5-FU and G-quadruplex ligands.
| Τίτλος: | Reversing uL3-mediated chemoresistance through synergistic combination of 5-FU and G-quadruplex ligands. |
|---|---|
| Συγγραφείς: | Di Porzio A; Department of Pharmacy, University of Naples Federico II, Via Domenico Montesano 49, 80131 Naples, Italy., Pecoraro A; Department of Pharmacy, University of Naples Federico II, Via Domenico Montesano 49, 80131 Naples, Italy., Danisi C; Department of Pharmacy, University of Naples Federico II, Via Domenico Montesano 49, 80131 Naples, Italy., Persico C; Department of Pharmacy, University of Naples Federico II, Via Domenico Montesano 49, 80131 Naples, Italy., D'Auria L; CEINGE-Biotecnologie Avanzate Franco Salvatore, Via Gaetano Salvatore 486 80131 Naples, Italy., Germoglio M; Department of Pharmacy, University of Naples Federico II, Via Domenico Montesano 49, 80131 Naples, Italy.; Istituto di Biochimica e Biologia Cellulare, Consiglio Nazionale delle Ricerche, Via Pietro Castellino 111, 80131 Naples, Italy., Iaccarino N; Department of Pharmacy, University of Naples Federico II, Via Domenico Montesano 49, 80131 Naples, Italy., Feliciello I; Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Sergio Pansini 5, 80131 Naples,Italy.; Department of Molecular Biology, Ruđer Bošković Institute, Bijenička 54, HR-10000 Zagreb, Croatia., Giancola C; Department of Pharmacy, University of Naples Federico II, Via Domenico Montesano 49, 80131 Naples, Italy., Randazzo A; Department of Pharmacy, University of Naples Federico II, Via Domenico Montesano 49, 80131 Naples, Italy., Russo G; Department of Pharmacy, University of Naples Federico II, Via Domenico Montesano 49, 80131 Naples, Italy., Russo A; Department of Pharmacy, University of Naples Federico II, Via Domenico Montesano 49, 80131 Naples, Italy. |
| Πηγή: | NAR cancer [NAR Cancer] 2025 Nov 28; Vol. 7 (4), pp. zcaf046. Date of Electronic Publication: 2025 Nov 28 (Print Publication: 2025). |
| Τύπος έκδοσης: | Journal Article; Research Support, Non-U.S. Gov't |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Oxford University Press Country of Publication: England NLM ID: 101769553 Publication Model: eCollection Cited Medium: Internet ISSN: 2632-8674 (Electronic) Linking ISSN: 26328674 NLM ISO Abbreviation: NAR Cancer Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Oxford : Oxford University Press, [2019]- |
| Ιατρικοί όροι (MeSH): | Fluorouracil*/pharmacology , Fluorouracil*/administration & dosage , Drug Resistance, Neoplasm*/drug effects , Drug Resistance, Neoplasm*/genetics , G-Quadruplexes*/drug effects , Colorectal Neoplasms*/drug therapy , Colorectal Neoplasms*/genetics , Colorectal Neoplasms*/pathology , Antineoplastic Combined Chemotherapy Protocols*/pharmacology , Ribosomal Proteins*/genetics , Ribosomal Proteins*/metabolism, Picolinic Acids/pharmacology ; Tumor Suppressor Protein p53/genetics ; Humans ; Animals ; Drug Synergism ; Ligands ; Xenograft Model Antitumor Assays ; Cell Line, Tumor ; Chick Embryo ; Ribosomal Protein L3 ; Mice ; Aminoquinolines |
| Περίληψη: | Chemoresistance represents a significant challenge in the chemotherapy of colorectal cancer (CRC), limiting the effectiveness. In this regard, gene expression heterogeneity plays a critical role, influencing cancer cell adaptability and survival under chemotherapy. Our previous data revealed that ribosomal protein uL3 positively correlates with both chemoresistance and poor prognosis in CRC patients. This study explores the combination of 5-fluorouracil (5-FU), the first-line treatment of CRC, with G-quadruplex (G4) ligands, which have recently emerged as promising candidates for cancer therapy, to overcome uL3-mediated chemoresistance. We found that resistant p53-deficient and uL3-silenced CRC cells showed increased levels of G4 structures compared to both sensitive p53-deficient and p53-proficient cells, thereby exhibiting vulnerability to the cytotoxic effects of two well-established G4 ligands, pyridostatin (PDS) and RHPS4. The combination of 5-FU with PDS or RHPS4 exhibited a synergistic effect, selectively targeting tumor cells. This approach enabled a >10-fold reduction in the 5-FU dose, improving treatment efficacy. The effectiveness of this combination was further validated in vivo using uL3-silenced CRC cell-derived xenografts in a chicken embryo model. Overall, our findings highlight a novel and promising combination strategy that targets chemoresistance in CRCs characterized by non-functional p53 and reduced levels of uL3. (© The Author(s) 2025. Published by Oxford University Press.) |
| Competing Interests: | None declared. |
| References: | Biomolecules. 2020 Apr 10;10(4):. (PMID: 32290083) Pharmaceuticals (Basel). 2024 Jun 13;17(6):. (PMID: 38931438) Trends Chem. 2020 Feb;2(2):123-136. (PMID: 32923997) Nat Commun. 2023 Jan 13;14(1):205. (PMID: 36639366) J Enzyme Inhib Med Chem. 2024 Dec;39(1):2366236. (PMID: 38905127) Nat Chem. 2013 Mar;5(3):182-6. (PMID: 23422559) Commun Chem. 2025 Mar 1;8(1):64. (PMID: 40025218) Biomolecules. 2021 Aug 27;11(9):. (PMID: 34572497) Cancer Drug Resist. 2023 Apr 29;6(2):257-272. (PMID: 37457133) Front Chem. 2018 Jul 24;6:281. (PMID: 30137743) Curr Pharm Des. 2012;18(14):1880-99. (PMID: 22376104) PLoS One. 2014 Jul 17;9(7):e102711. (PMID: 25033211) Eur J Pharmacol. 2014 Feb 15;725:64-9. (PMID: 24440533) J Gastrointest Oncol. 2024 Feb 29;15(1):286-298. (PMID: 38482213) ChemMedChem. 2018 Mar 6;13(5):406-410. (PMID: 29345419) Trends Genet. 2023 Jan;39(1):15-30. (PMID: 36414480) J Biol Inorg Chem. 2023 Mar;28(2):117-138. (PMID: 36456886) BMC Cancer. 2022 Aug 31;22(1):940. (PMID: 36045334) Oncotarget. 2016 Nov 29;7(48):79670-79687. (PMID: 27835895) Int J Mol Sci. 2021 Nov 04;22(21):. (PMID: 34769387) Signal Transduct Target Ther. 2025 Jun 11;10(1):190. (PMID: 40500258) Cell Death Differ. 2022 May;29(5):972-982. (PMID: 35444234) Int J Mol Sci. 2021 Jun 30;22(13):. (PMID: 34208896) Eur J Med Chem. 2025 Mar 5;285:117245. (PMID: 39793440) Oncotarget. 2016 Aug 2;7(31):50333-50348. (PMID: 27385096) NAR Cancer. 2024 Oct 30;6(4):zcae042. (PMID: 39478935) Antioxidants (Basel). 2024 Jun 22;13(7):. (PMID: 39061826) J Med Chem. 2024 Feb 8;67(3):1812-1824. (PMID: 38285632) Chem Commun (Camb). 2022 Oct 25;58(85):11913-11916. (PMID: 36196950) J Biol Chem. 2016 Aug 19;291(34):18041-57. (PMID: 27369081) J Am Chem Soc. 2008 Nov 26;130(47):15758-9. (PMID: 18975896) Adv Enzyme Regul. 1984;22:27-55. (PMID: 6382953) Cancer Cell Int. 2020 Jan 29;20:30. (PMID: 32015690) Mutat Res. 2014 Aug-Sep;766-767:7-13. (PMID: 25847265) Nucleic Acids Res. 2023 Aug 11;51(14):7392-7408. (PMID: 37351621) Angew Chem Int Ed Engl. 2024 Oct 7;63(41):e202408581. (PMID: 39012206) Curr Med Chem. 2019;26(16):2918-2932. (PMID: 29493440) Mol Pharm. 2023 May 1;20(5):2326-2340. (PMID: 36976623) Sci Rep. 2019 Oct 28;9(1):15431. (PMID: 31659203) Cancer Res. 2010 Jan 15;70(2):440-6. (PMID: 20068163) Int J Mol Sci. 2021 Aug 27;22(17):. (PMID: 34502219) Int J Mol Sci. 2021 Sep 24;22(19):. (PMID: 34638655) J Med Chem. 2025 Jan 23;68(2):1245-1259. (PMID: 39743313) FEBS J. 2010 Sep;277(17):3452-8. (PMID: 20670279) Signal Transduct Target Ther. 2024 Dec 4;9(1):340. (PMID: 39627201) Genes Dis. 2022 Mar 18;10(4):1367-1401. (PMID: 37397557) Cancer Cell Int. 2021 Dec 24;21(1):703. (PMID: 34952583) BMC Cancer. 2020 Nov 25;20(1):1149. (PMID: 33238958) Life Sci. 2024 Mar 1;340:122481. (PMID: 38301873) Molecules. 2025 Apr 17;30(8):. (PMID: 40333779) Signal Transduct Target Ther. 2023 Mar 1;8(1):92. (PMID: 36859359) Eur J Pharm Sci. 2025 Sep 01;212:107204. (PMID: 40675344) Nucleic Acids Res. 2015 Oct 15;43(18):8627-37. (PMID: 26350216) Oncol Lett. 2018 Jul;16(1):9-18. (PMID: 29928381) Cell Death Differ. 2018 Jan;25(1):104-113. (PMID: 29149101) J Clin Invest. 2007 Nov;117(11):3236-47. (PMID: 17932567) Front Biosci (Landmark Ed). 2024 Jul 25;29(7):272. (PMID: 39082342) Oncotarget. 2014 Nov 30;5(22):11737-51. (PMID: 25473889) Sci Rep. 2019 Apr 3;9(1):5605. (PMID: 30944353) Genome Biol. 2025 Jul 12;26(1):183. (PMID: 40646632) Explor Target Antitumor Ther. 2020;1(1):53-70. (PMID: 36046264) Analyst. 2019 Nov 4;144(22):6512-6516. (PMID: 31602449) Mol Cancer. 2021 Feb 25;20(1):40. (PMID: 33632214) NAR Cancer. 2021 Sep 16;3(3):zcab038. (PMID: 34541539) Int J Mol Sci. 2020 Mar 20;21(6):. (PMID: 32244996) Sci Rep. 2016 Dec 07;6:38369. (PMID: 27924828) Nucleic Acids Res. 2019 May 7;47(8):3862-3874. (PMID: 30892612) Expert Opin Ther Pat. 2023 Nov;33(11):745-773. (PMID: 37855085) |
| Substance Nomenclature: | U3P01618RT (Fluorouracil) 0 (Ligands) 0 (pyridostatin) 0 (Picolinic Acids) 0 (RPL3 protein, human) 0 (Tumor Suppressor Protein p53) 0 (Ribosomal Proteins) 0 (Ribosomal Protein L3) 0 (Aminoquinolines) |
| Entry Date(s): | Date Created: 20251201 Date Completed: 20251201 Latest Revision: 20260707 |
| Update Code: | 20260708 |
| PubMed Central ID: | PMC12661320 |
| DOI: | 10.1093/narcan/zcaf046 |
| PMID: | 41322077 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!